ProfileGDS5678 / 1457275_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 73% 74% 53% 53% 46% 53% 57% 58% 62% 72% 69% 64% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7071661
GSM967853U87-EV human glioblastoma xenograft - Control 24.7033173
GSM967854U87-EV human glioblastoma xenograft - Control 34.7938574
GSM967855U87-EV human glioblastoma xenograft - Control 43.2419953
GSM967856U87-EV human glioblastoma xenograft - Control 53.2594653
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1716746
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4016653
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4688657
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5077758
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6811462
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5440472
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3178469
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8626664
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5235259